Double Bond Pharmaceutical receives patent in the United States for the BeloGal® platform
Double Bond Pharmaceuticals patent application for organ-specific administration of hydrophilic cancer drug to the liver which forms the basis for the BeloGal® technology platform has been granted in the United States. Patent approval provides protection for the technology platform BeloGal® and products on the US market at least through 2035.
“It is the company’s first licensed patent and we are very pleased that it concerns the largest market in the world – the United States. With the patent, we have achieved an important interim goal for the commercialization of our front-line product SA-033 for the treatment of cancer in the liver. In addition to the US patent, we also have applications under review in both Europe, Asia and other important markets.” comments Igor Lokot, CEO of Double Bond Pharmaceutical.
More about SA-033
SA-033 is the first drug candidate that DBP has developed using its innovative drug delivery technology BeloGal®. Due to innovative formulation controls targeting of doxorubicin to the liver, the concentration of the active substance in the desired target organ increases, which enhances efficacy and reduces the toxic side effects that are common in systemic chemotherapy.
More about BeloGal®
BeloGal® is DBP’s innovative drug-delivery platform which targets pharmaceutically active compounds to lung or liver.
This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 31 of July 2018.
Contact information
Full Company Name:
Double Bond Pharmaceutical International AB (publ)
Corporate identity:
556991-6082
Stock short name:
DBP B
Share ISIN code:
SE0007185525
For more info, contact
Igor Lokot, CEO
Homepage:
E-mail:
Blog:
Follow us on:
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.